37 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
4 May 23
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:06pm
expenses on clinical supply manufacturing, partially offset by increased compensation expenses.
General and administrative expenses for the first quarter … , partially offset by lower Director & Officer Liability insurance and other expenses.
The Company reported a net loss of $6.2 million, or $(0.21
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
26 Mar 24
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
7:12am
research, partially offset by decreased manufacturing costs.
General and administrative expenses were $13.5 million for the year ended December 31, 2023 … and equity-based compensation, partially offset by decreased Director & Officer Liability insurance and other expenses.
The Company reported a net loss
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
11 May 22
Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
7:06am
trial activity. This amount was offset in part by lower CMC costs as compared to 2021.
General and administrative expenses for the first quarter ended
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
2 Nov 23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:41am
, 2022. The decrease was primarily related to lower professional fees, Director & Officer Liability insurance partially offset by increased equity-based
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
9 Aug 22
Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
7:15am
efforts. This was also offset by a decrease in manufacturing expenses for pre-clinical and future clinical trial materials associated with the Company’s
8-K
EX-99.1
sejei
8 Aug 23
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
7:05am
DRS/A
EX-10.30
d9pzq xomnyu65
23 Jun 21
Draft registration statement (amended)
12:00am
S-1
EX-10.33
fjlhc4tm19
19 Jul 21
IPO registration
7:02am
DRS/A
EX-10.28
h634 ndzk
23 Jun 21
Draft registration statement (amended)
12:00am
S-1
EX-10.31
al2p 6hpgm
19 Jul 21
IPO registration
7:02am
DRS/A
EX-10.31
4n9i8 jlw1
23 Jun 21
Draft registration statement (amended)
12:00am
S-1
EX-10.34
zwe2tl7
19 Jul 21
IPO registration
7:02am
DRS/A
EX-10.29
6bdtd fvvy80xsplb
23 Jun 21
Draft registration statement (amended)
12:00am
S-1
EX-10.32
4oozo kn83mjl
19 Jul 21
IPO registration
7:02am